Lung Imaging in COPD Part 1

Raoof, Suhail; Shah, Manav; Make, Barry J.; Allaqaband, Hassan; Bowler, Russell P.; Fernando, Shannon M.; Greenberg, Harly; Han, MeiLan K.; Hogg, James; Humphries, Stephen; Lee, Kyung Soo; Lynch, David A.; Machnicki, Stephen; Mehta, Atul C.; Mina, Bushra; Naidich, David P.; Naidich, Jason J.; Naqvi, Zarnab; Ohno, Yoshiharu; Regan, Elizabeth A.; Travis, William D.; Washko, George R.; Braman, Sidney S.

doi:10.1016/j.chest.2023.03.007

Cited by 14 publications

(2 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marked hyperinflation is most often seen on plain chest radiographs in emphysema [ 8 ]. CT imaging has a greater sensitivity and specificity than chest radiography in determining the type, extent and distribution of emphysema ( figure 4 ) [ 34 ].…”

Section: Concomitant Copdmentioning

confidence: 99%

The role of radiological imaging in the management of severe and difficult-to-treat asthma

Aigbirior,

Almaghrabi,

Lafi

et al. 2024

Breathe

View full text Add to dashboard Cite

Radiological imaging has proven to be a useful tool in the assessment of asthma, its comorbidities and potential complications. Characteristic chest radiograph and computed tomography scan findings can be seen in asthma and in other conditions that can coexist with or be misdiagnosed as asthma, including chronic rhinosinusitis, inducible laryngeal obstruction, excessive dynamic airway collapse, tracheobronchomalacia, concomitant COPD, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, and eosinophilic pneumonia. The identification of the characteristic radiological findings of these conditions is often essential in making the correct diagnosis and provision of appropriate management and treatment. Furthermore, radiological imaging modalities can be used to monitor response to therapy.

show abstract

Section: Concomitant Copdmentioning

confidence: 99%

The role of radiological imaging in the management of severe and difficult-to-treat asthma

Aigbirior,

Almaghrabi,

Lafi

et al. 2024

Breathe

View full text Add to dashboard Cite

show abstract

“…COPD is among the top third causes of death, according to the World Health Organization (WHO) [2]. The disease is characterized by small airway complications such as obstructive bronchiolitis, fibrosis, airway remodeling, and emphysema [3]. The clinical manifestations of COPD vary among different patients [4], and an accelerated decline in lung function is observed in approximately half of patients [5].…”

Section: Introductionmentioning

confidence: 99%

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics

Ahmadi,

Ahrari,

Salimian

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing immune responses are significant contributors to the development and progression of the disease. The p38 isoforms are regarded as pivotal hub proteins that regulate immune and inflammatory responses in both healthy and disease states. As a result, their inhibition has been the subject of numerous recent studies exploring their therapeutic potential in COPD. Main body We performed a systematic search based on the PRISMA guidelines to find relevant studies about P38 signaling in COPD patients. We searched the PubMed and Google Scholar databases and used “P38” AND “COPD” Mesh Terms. We applied the following inclusion criteria: (1) human, animal, ex vivo and in vitro studies; (2) original research articles; (3) published in English; and (4) focused on P38 signaling in COPD pathogenesis, progression, or treatment. We screened the titles and abstracts of the retrieved studies and assessed the full texts of the eligible studies for quality and relevance. We extracted the following data from each study: authors, year, country, sample size, study design, cell type, intervention, outcome, and main findings. We classified the studies according to the role of different cells and treatments in P38 signaling in COPD. Conclusion While targeting p38 MAPK has demonstrated some therapeutic potential in COPD, its efficacy is limited. Nevertheless, combining p38 MAPK inhibitors with other anti-inflammatory steroids appears to be a promising treatment choice. Clinical trials testing various p38 MAPK inhibitors have produced mixed results, with some showing improvement in lung function and reduction in exacerbations in COPD patients. Despite these mixed results, research on p38 MAPK inhibitors is still a major area of study to develop new and more effective therapies for COPD. As our understanding of COPD evolves, we may gain a better understanding of how to utilize p38 MAPK inhibitors to treat this disease.

show abstract